Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Nektar Therapeutics    NKTR

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Insider Trading Activity Nektar Therapeutics (NASDAQ:NKTR) – Director Sold 30,000 shares of Stock

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/19/2017 | 04:53am CEST

Insider Trading Activity For Nektar Therapeutics (NASDAQ:NKTR)

Lutz Lingnau , Director of Nektar Therapeutics (NASDAQ:NKTR) reportedly Sold 30,000 shares of the company’s stock at an average price of 20.76 for a total transaction amount of $622,800.00 SEC Form

Insider Trading History For Nektar Therapeutics (NASDAQ:NKTR)

  • On 9/14/2012 Dennis L Winger, Director, bought 5,000 with an average share price of $9.18 per share and the total transaction amounting to $45,900.00.View SEC Filing
  • On 8/5/2013 Roy Whitfield, Director, sold 12,500 with an average share price of $12.41 per share and the total transaction amounting to $155,125.00.View SEC Filing
  • On 11/3/2014 Gil M Labrucherie, SVP, sold 9,900 with an average share price of $13.78 per share and the total transaction amounting to $136,422.00.View SEC Filing
  • On 11/24/2014 Lutz Lingnau, Director, sold 15,000 with an average share price of $15.02 per share and the total transaction amounting to $225,300.00.View SEC Filing
  • On 11/24/2014 Howard W Robin, CEO, sold 132,800 with an average share price of $15.02 per share and the total transaction amounting to $1,994,656.00.View SEC Filing
  • On 11/24/2014 Gil M Labrucherie, SVP, sold 10,500 with an average share price of $15.04 per share and the total transaction amounting to $157,920.00.View SEC Filing
  • On 11/25/2014 Howard W Robin, CEO, sold 600,000 with an average share price of $15.25 per share and the total transaction amounting to $9,150,000.00.View SEC Filing
  • Analyst Ratings For Nektar Therapeutics (NASDAQ:NKTR)
    These are 8 Buy Ratings .
    The current consensus rating for Nektar Therapeutics (NASDAQ:NKTR) is Buy (Score: 3.00) with a consensus target price of $26.29 , a potential (21.69% upside)

    Analyst Ratings History For Nektar Therapeutics (NASDAQ:NKTR)

    • On 1/27/2016 Janney Montgomery Scott Initiated Coverage of rating Buy with a price target of $21.00
    • On 9/30/2016 Brean Capital Reiterated Rating Buy with a price target of $23.00
    • On 3/21/2017 J P Morgan Chase & Co Set Price Target of rating Buy with a price target of $24.00
    • On 3/21/2017 BTIG Research Boost Price Target of rating Positive with a price target of $22.00 to $27.00
    • On 4/11/2017 Piper Jaffray Companies Reiterated Rating Overweight with a price target of $29.00
    • On 5/10/2017 Aegis Reiterated Rating Buy with a price target of $27.00
    • On 5/10/2017 Jefferies Group LLC Lower Price Target of rating Buy with a price target of $25.00 to $23.00

    Recent Trading Activity for Nektar Therapeutics (NASDAQ:NKTR)
    Shares of Nektar Therapeutics closed the previous trading session at 21.60 up +0.94 4.55% with 2,202,643 shares trading hands.

    The post Insider Trading Activity Nektar Therapeutics (NASDAQ:NKTR) – Director Sold 30,000 shares of Stock appeared first on Market Exclusive.

    © Market Exclusive 2017, source Market Exclusive

    share with twitter share with LinkedIn share with facebook
    share via e-mail
    0
    Latest news on NEKTAR THERAPEUTICS
    07/19 INSIDER TRADING ACTIVITY NEKTAR THER : NKTR) – Director Sold 30,000 shares..
    07/18 NEKTAR THERAPEUTICS (NASDAQ : NKTR) Files An 8-K Regulation FD Disclosure
    07/18 NEKTAR THERAPEUTICS : Announces Topline Data from Human Abuse Potential Study fo..
    07/18 NEKTAR THERAPEUTICS : Regulation FD Disclosure, Financial Statements and Exhibit..
    07/12 NEKTAR THERAPEUTICS : Today's Research Reports on Trending Tickers: Nektar Thera..
    07/10 NEKTAR THERAPEUTICS : Presents New Preclinical Data for NKTR-358, a First-in-Cla..
    07/07 NEKTAR THERAPEUTICS : Daily Technical Summary Reports on Biotech Stocks -- Juno ..
    06/15 NEKTAR THERAPEUTICS : Change in Directors or Principal Officers, Submission of M..
    06/15 NEKTAR THERAPEUTICS : Presents New Clinical Data from Two Studies of NKTR-214, a..
    06/06 NEKTAR THERAPEUTICS : to Webcast Presentation at Jefferies 2017 Global Healthcar..
    More news
    News from SeekingAlpha
    07/18 Nektar Therapeutics (NKTR) Updates On Topline Results of Oral Human Abuse Pot..
    07/18 HAP study confirms the value proposition of Nektar's euphoria-lite opioid can..
    07/10 26 Stocks For July 2017
    07/06 Q3 BIOTECH CATALYST WATCH : Phase 3 Data Releases (Part 2)
    06/14 NEKTAR THERAPEUTICS : A Sweet Or Sour Investment?
    Financials ($)
    Sales 2017 165 M
    EBIT 2017 -141 M
    Net income 2017 -181 M
    Debt 2017 214 M
    Yield 2017 -
    P/E ratio 2017 -
    P/E ratio 2018
    EV / Sales 2017 21,6x
    EV / Sales 2018 18,6x
    Capitalization 3 361 M
    Chart NEKTAR THERAPEUTICS
    Duration : Period :
    Nektar Therapeutics Technical Analysis Chart | NKTR | US6402681083 | 4-Traders
    Technical analysis trends NEKTAR THERAPEUTICS
    Short TermMid-TermLong Term
    TrendsBullishBullishBullish
    Income Statement Evolution
    Consensus
    Sell
    Buy
    Mean consensus BUY
    Number of Analysts 8
    Average target price 24,3 $
    Spread / Average Target 12%
    EPS Revisions
    Managers
    NameTitle
    Howard W. Robin President, Chief Executive Officer & Director
    Robert B. Chess Chairman
    John Nicholson Chief Operating Officer & Senior Vice President
    Gilbert M. Labrucherie Chief Financial Officer & Senior Vice President
    Stephen K. Doberstein Chief Scientific Officer & Senior Vice President
    Sector and Competitors
    1st jan.Capitalization (M$)
    NEKTAR THERAPEUTICS76.53%3 361
    INCYTE CORPORATION30.10%26 713
    QUINTILES IMS HOLDINGS INC18.44%19 631
    LONZA GROUP31.29%16 937
    CELLTRION, INC.--.--%12 502
    ALKERMES PLC4.37%8 827